foxo4 dri human trial senolytic

foxo4 dri human trial senolytic Molecular modelling of the FOXO4-TP53 interaction to design peptides for the elimination of senescent cancer cells FOXO4-DRI: Human Trial Status, Cancer

Name: foxo4 dri human trial senolytic Molecular modelling of the FOXO4-TP53 interaction to design peptides for the elimination of senescent cancer cells FOXO4-DRI: Human Trial Status, Cancer
Brand: www.asociacionchamorro.org
SKU: 71286671790
Price: 27.56 USD
Availability: InStock
Rating: 4.772200000000001 (15 reviews)

FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect Emerging strategies in senotherapeutics: from broad spectrum senolysis to precision reprogramming npj Aging Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine

SKU: 71286671790 · From www.asociacionchamorro.org

4.8

USD27.56 USD59.56

Pay in 4 interest-free payments of $6.89 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 11 - Aug 16

Description

Generative AI statement The author(s) declare that no Generative AI was used in the creation of this manuscript

Dobarro M, Gerenu G, Ramrez MJ

Form: Lyophilized powder Total compound mass : 216 mg Purity : 99% analytical verification Packaging: Sterile sealed vial Manufacturing standard : Controlled laboratory production Storage: Refrigerated (28C) Quality Assurance and Analytical Testing Each batch of LC216 undergoes analytical verification to support research transparency and reproducibility